Burkholderia mallei lipopolysaccharide (LPS) has been previously shown to cross-react with polyclonal antibodies raised against B. pseudomallei LPS; however, we observed that B. mallei LPS does not react with a monoclonal antibody (Pp-PS-W) specific for B. pseudomallei O polysaccharide (O-PS). In this study, we identified the O-PS biosynthetic gene cluster from B. mallei ATCC 23344 and subsequently characterized the molecular structure of the O-PS produced by this organism.
the anti-LPS polyclonal sera, as indicated by the absence of bands (Fig. 1B) . In order to confirm that the O-PS moiety was absent rather than a different type of O-PS, silver stain analysis was employed. Figure 1C shows the silver stain results confirming that both of these strains lacked O-PS moieties.
Identification and characterization of B. mallei ATCC 23344 O-PS biosynthetic gene cluster. In order to investigate the genes responsible for O-PS biosynthesis in B. mallei, we constructed a cosmid library by using B. mallei ATCC 23344 genomic DNA and the cosmid pScosBC1 by using a previously described protocol (12) . Colony hybridizations were then performed with a 1.1-kb DNA fragment containing the recently identified B. mallei wbiA gene (P. Brett, M. Burtnick, and D. Woods, unpublished data). Six positive cosmid clones were obtained. Based on the BamHI-KpnI restriction patterns obtained, two cosmid clones, 1C3 and 2B5, were predicted to harbor the entire B. mallei O-PS gene cluster. Sequence analysis resulted in 19,918 bp of contiguous sequence containing the entire B. mallei O-PS biosynthetic gene cluster with an IS407-like insertion sequence element at the 3Ј end.
The first 18,738 bp of the B. mallei DNA sequence contained 16 predicted ORFs that were identical to those previously defined as the O-PS biosynthetic gene cluster in B. pseudomallei ( Fig. 2) (5) . Sequence alignment of the B. pseudomallei and B. mallei O-PS biosynthetic regions revealed 99% identity at the nucleotide level. The genes comprising the B. mallei O-PS biosynthetic operon were named as per the identical genes found in B. pseudomallei (5) .
Physical characterization of B. mallei O-PS moieties. In order to structurally analyze the B. mallei O-PS structure, it was necessary to construct a B. mallei strain unable to produce capsular polysaccharide (CPS), because CPS copurifies with LPS. The suicide vector pGSV3008 was employed as previously described to construct B. mallei PB100, a derivative of ATCC 23344 that does not produce CPS (6) . The O-PS was purified as previously described for B. pseudomallei. B. mallei survives in 30% NHS, and serum-sensitive strains lack the O-PS moiety of LPS. The ability of B. mallei ATCC 23344 to grow in the presence of 30% normal human serum (NHS) was initially assessed with a serum bactericidal assay (5) in which viable counts were determined at 2, 4, 8, and 18 h. B. mallei ATCC 23344 was shown to survive in the presence of 30% NHS over the course of 18 h (Fig. 4A) . Serum-resistant B. pseudomallei 1026b and serum-sensitive Escherichia coli HB101 were employed as controls.
In order to assess the role of B. mallei O-PS in serum resistance, NHS bactericidal assays (5) were performed with B. mallei ATCC 23344 and B. mallei NCTC 120 and ATCC 15310, the two strains lacking O-PS. B. mallei ATCC 23344 remained resistant to the killing action of 30% NHS, while NCTC 120 and ATCC 15310 were completely killed following a 2-h incubation in 30% NHS (Fig. 4B) . The other seven B. mallei strains used in this study possessed intact O-PS moieties and were resistant to the bactericidal action of 30% NHS (data not shown). These results suggested that B. mallei O-PS moieties play a crucial role in the serum resistance of this organism: this correlates well with previous studies demonstrating that B. pseudomallei O-PS is required for serum resistance (5) . (6) . The data presented in this paper certainly support the view that IS407 is functionally active in B. mallei. We are grateful to Patricia Baker and Francois Becotte for excellent technical assistance. We thank David DeShazer for providing us with the plasmid pGSV3008. 
